Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04877288 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

A Phase 3 study of Renal Allograft Recipients, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 3
Development phase
102
Enrollment target
20
Study locations

NCT04877288: Recruiting Phase 3 study of Renal Allograft Recipients, sponsored by Bristol-Myers Squibb.

NCT04877288 is a Phase 3 study of Renal Allograft Recipients that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 102 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04877288, a Phase 3 study of Renal Allograft Recipients, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 3
Development phase
102 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin inhibitor-based regimen and their adherence to immunosuppressive medications.

Conditions Studied

Renal Allograft Recipients

Interventions

  • DRUG Mycophenolate Mofetil
  • DRUG Tacrolimus
  • DRUG Cyclosporine A
  • BIOLOGICAL Belatacept
  • DRUG Enteric Coated Mycophenolate Sodium

Study Locations (20)

Other

  • Local Institution - 0062 - Buenos Aires
  • UZ Gent-Paediatric Nephrology and Rheumatology Department - Ghent
  • Bordeaux University Hospital - Pellegrin-Pediatrics - Bordeaux

Florida

  • Local Institution - 0022 - Hollywood
  • Local Institution - 0045 - Miami

Ohio

  • Local Institution - 0025 - Cincinnati
  • Local Institution - 0048 - Cleveland

Alabama

  • Local Institution - 0042 - Birmingham

California

  • Local Institution - 0041 - Los Angeles

District of Columbia

  • Local Institution - 0014 - Washington D.C.

Georgia

  • Local Institution - 0049 - Atlanta

Illinois

  • Local Institution - 0033 - Chicago

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2021-07-21
Est. Completion 2034-06-30
Phase Phase 3
Bristol-Myers Squibb

1,025 total trials

What NCT04877288 shows while recruiting

NCT04877288 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Renal Allograft Recipients appearing as the primary indexed condition, and to 5 interventions - of which Mycophenolate Mofetil is the first listed.

NCT04877288 names 20 study sites across 16 states, led by Other, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT04877288 about?

NCT04877288 is a clinical study titled "A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications". The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin inhibitor-based regimen and their adheren...

What is the current status of trial NCT04877288?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2021-07-21. Estimated completion is 2034-06-30.

What conditions does trial NCT04877288 study?

This clinical trial studies the following conditions: Renal Allograft Recipients.

What interventions are being tested in trial NCT04877288?

The interventions under investigation include: Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Cyclosporine A (DRUG), Belatacept (BIOLOGICAL), Enteric Coated Mycophenolate Sodium (DRUG).

Who is sponsoring clinical trial NCT04877288?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04877288 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT04877288's enrollment target sits among peer trials

102 1677th of 2000 higher than 321 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03704662 · 102 participants · NA

    Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

  • NCT04174742 · 102 participants

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  • NCT04275362 · 102 participants

    Gait Analysis of a Lateral-Pivot Design Total Knee Replacement

  • NCT04541082 · 102 participants · Phase 1

    Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04877288

Source: ClinicalTrials.gov NCT04877288, the US trial registry maintained by the National Library of Medicine. NCT04877288 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.